Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Sequential Parallel Group, Single and Multiple Ascending Dose (SAD/MAD) Study in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics of HL-400 Following Oral Administration

NCT06997484 is registered in ClinicalTrials.gov with Highlightll Pharmaceutical (USA) LLC as lead sponsor.

NCT NCT06997484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06997484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Sequential Parallel Group, Single and Multiple Ascending Dose (SAD/MAD) Study in Healthy Subjects to Evaluate the Safety, Tolerability, Pharmacokinetics of HL-400 Following Oral Administration
Lead sponsor
Highlightll Pharmaceutical (USA) LLC
Phase
Phase 1
Overall status
Recruiting
Start date
April 25, 2025
Completion date
October 27, 2026
Enrollment
86 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease